Roivant Sciences Stock (NASDAQ:ROIV)
Previous Close
$11.68
52W Range
$8.46 - $13.05
50D Avg
$11.81
200D Avg
$11.12
Market Cap
$8.53B
Avg Vol (3M)
$5.94M
Beta
1.25
Div Yield
-
ROIV Company Profile
Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.
ROIV Performance
Peer Comparison
| Ticker | Company |
|---|---|
| PLRX | Pliant Therapeutics, Inc. |
| AKRO | Akero Therapeutics, Inc. |
| CGEM | Cullinan Oncology, Inc. |
| RVMD | Revolution Medicines, Inc. Warrant |
| VRDN | Viridian Therapeutics, Inc. |
| APLS | Apellis Pharmaceuticals, Inc. |
| BPMC | Blueprint Medicines Corporation |
| DAWN | Day One Biopharmaceuticals, Inc. |
| PHAT | Phathom Pharmaceuticals, Inc. |
| BGNE | BeiGene, Ltd. |
| SNDX | Syndax Pharmaceuticals, Inc. |
| RXDX | Prometheus Biosciences, Inc. |
| INZY | Inozyme Pharma, Inc. |
| ASND | Ascendis Pharma A/S |
| KRYS | Krystal Biotech, Inc. |
| LYRA | Lyra Therapeutics, Inc. |